A separate, sterile syringe and needle or a sterile disposable unit must be used for each patient to prevent transmission of hepatitis or other infectious agents from person to person. Needles should not be recapped and should be properly disposed. No studies have been performed to evaluate carcinogenicity, mutagenic potential, or impact on fertility. It is also not known whether Tetanus Toxoid USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Tetanus Toxoid USP should be given to a pregnant woman only if clearly needed.
Physicians generally avoid prescribing unnecessary drugs and biologics for pregnant women.
Pregnant women in similar circumstances who have not had a complete vaccination series should complete the three- dose series. Those vaccinated more than 10 years previously should have a booster dose. No evidence exists to indicate that tetanus and diphtheria toxoids administered during pregnancy are teratogenic. It has been reported that Tetanus Toxoid administered to pregnant women prevents neonatal tetanus in newborns. However, the data reported on the safety of Tetanus Toxoid when so used is inconclusive because the incidence of neonatal deaths in New Guinea was significantly higher than in the United States.